Royal Bank Of Canada Champions Oncology, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.5 - $5.23 $310 - $360	69 Added 107.81%	133 $0
Q1 2024 Nov 05, 2024	SELL	$4.9 - $6.91 $338 - $476	-69 Reduced 51.88%	64 $0
Q1 2024 May 15, 2024	SELL	$4.9 - $6.91 $764 - $1,077	-156 Reduced 70.91%	64 $0
Q4 2023 Feb 14, 2024	BUY	$4.56 - $6.59 $880 - $1,271	193 Added 714.81%	220 $1,000
Q3 2023 Nov 14, 2023	SELL	$5.2 - $7.32 $1,034 - $1,456	-199 Reduced 88.05%	27 $0
Q2 2023 Aug 14, 2023	SELL	$4.11 - $6.81 $5,918 - $9,806	-1,440 Reduced 86.43%	226 $1,000
Q1 2023 May 15, 2023	BUY	$4.0 - $4.67 $6,072 - $7,089	1,518 Added 1025.68%	1,666 $6,000
Q4 2022 Feb 14, 2023	SELL	$3.75 - $7.69 $112 - $230	-30 Reduced 16.85%	148 $0
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.47 $562 - $738	78 Added 78.0%	178 $2,000
Q4 2021 Feb 14, 2022	SELL	$7.76 - $10.23 $194 - $255	-25 Reduced 20.0%	100 $1,000
Q3 2021 Nov 15, 2021	SELL	$9.11 - $10.96 $11,196 - $13,469	-1,229 Reduced 90.77%	125 $1,000
Q2 2021 Aug 16, 2021	BUY	$8.45 - $11.72 $11,441 - $15,868	1,354 New	1,354 $14,000

5.82M

15K

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $102M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.